A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms(LUTS) Due to Benign Prostatic Hypertrophy (BPH)

Study start date: January 23, 2007

Inclusion Criteria: - All of the following questions must be answered "Yes" at Visit 1 in order for the participant to participate in the study. * Is the participant at least 50 years old? * Does the participant have clinical signs and symptoms consistent with BPH? * Does the participant have an IPSS 13 at screening (prior to placebo run in)? * Does the participant have a peak urinary flow rate (Qmax) of 4-15 milliliter/second (mL/sec) established on a voided volume of at least 125 mL? * Is the participant willing to agree not to use any other approved or experimental pharmacologic BPH treatments including alpha blockers, 5-alpha reductase inhibitors, anti-cholinergic preparations or herbal preparations at any time during the study? Exclusion Criteria: All of the following questions must be answered "No" at Visit 1 in order for the participant to participate in the study. * Does the participant have a history of prostate cancer or a serum PSA \>10 nanograms per milliliter (ng/mL)? * Has the participant had prior prostate or bladder surgery, pelvic surgery (excluding hernia repair), pelvic radiation or lower urinary tract malignancy? * Does the participant have a prevoid total bladder volume assessed by ultrasound \> 550 mL? * Does the participant have a residual urine volume \> 350 mL by ultrasound?